For instance, Pembrolizumab, a humanized IgG4/kappa anti-PD1, is indicated as frontline therapy for advanced melanoma, for PD-L1 ≥ 50% advanced non-small cell lung carcinoma and for cisplatin-ineligible patient with advanced urothelial cancer. Here, PDCD1 is linked to non-small cell lung carcinoma.